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We estimated 30-day all-cause and Clostridium difficile infection 
(CDI)–associated hospital readmissions in participants at high 
risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-
treated inpatients experienced fewer CDI-associated readmis-
sions compared with placebo-treated inpatients, notably in 
participants aged ≥65 years and with severe CDI. 
Clinical Trials Registration. NCT01241552 (MODIFY I) 
and NCT01513239 (MODIFY II).
Keywords. C. difficile infection; recurrence; hospital read-
missions; bezlotoxumab. 
Although antibiotic treatment of primary Clostridium diffi-
cile infection (CDI) is often successful, approximately 25% of 
patients experience recurrent CDI (rCDI) after completing ini-
tial antibiotic therapy [1, 2]. After a first recurrence of CDI, the 
probability of a second recurrence is approximately 38% [3]. 
Known risk factors for rCDI include concomitant systemic anti-
biotic use [4], advanced age [5, 6], inadequate immune response 
to antitoxins [7, 8], severe underlying disease [9], and infection 
with the BI/NAP1/027 strain [6, 10–12].
Recent model-based estimates place the 2014 economic cost 
of CDI at $5.4 billion in the United States, mostly attributable 
to hospitalization [13]. In Europe, extra per-patient costs for 
treatment of CDI were reported to reach €4396 to €14 023, 
with the majority of costs due to hospitalization [14, 15]. In 
France, 12.5% of the €163.1 million extra cost of CDI in public 
acute-care hospitals was attributable to rCDI [15]. Episodes of 
rCDI are associated with excessive costs, mostly attributable to 
significantly longer hospital stays, especially in intensive care 
units in tertiary care settings [16–18]. Hospital readmissions 
are more common among patients with a CDI discharge diag-
nosis than among those without one [19] and may contribute 
to the disease burden. Patients with rCDI are also significantly 
more likely than patients with nonrecurrent CDI to experience 
a readmission [20].
MODIFY I  and MODIFY II were global trials that investi-
gated the efficacy and safety of bezlotoxumab, a human mon-
oclonal antibody against C. difficile toxin B, for the prevention 
of rCDI in adults receiving antibacterial drug treatment [21]. In 
the MODIFY trials, bezlotoxumab significantly reduced rCDI 
(P < .001, both studies) and had a favorable safety profile [21]. 
The objective of the current analysis was to estimate 30-day 
CDI-associated hospital readmission rates and all-cause hos-
pital readmission rates using pooled data from the MODIFY 
I/MODIFY II trials in the subgroup of participants who were 
inpatients at the time of study randomization and for partici-
pants who had high-risk prognostic factors for rCDI.
METHODS
MODIFY I (NCT01241552) and MODIFY II (NCT01513239) 
were randomized, double-blind, placebo-controlled, multi-
center, global phase 3 trials conducted from 1 November 2011 
through 22 May 2015 at 322 sites in 30 countries. The protocols 
and all amendments were approved by the institutional review 
board or independent ethics committee at each study center. 
Each study was conducted in accordance with Good Clinical 
Practice guidelines and the Declaration of Helsinki. Written 
informed consent was obtained before study procedures were 
performed.
The eligibility criteria for the MODIFY trials have been 
described elsewhere [21]. Briefly, adults with primary CDI or 
rCDI receiving antibiotic treatment for CDI (determined by the 
treating physician) were enrolled. CDI was defined as diarrhea 
(≥3 unformed bowel movements in 24 hours) associated with 
a positive stool test for toxigenic C. difficile. The number of 
unformed bowel movements was recorded by participants daily 
for 80–90 days, and new episodes of diarrhea were monitored 
via scheduled phone contacts between visits.
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Participants included in the MODIFY trials received 1 
dose of bezlotoxumab (10  mg/kg) or placebo (0.9% saline). 
Randomization was stratified by oral antibacterial drug 
treatment for CDI and hospitalization status (inpatient or 
outpatient).
Thirty-Day readmissions is an emerging policy-relevant 
quality metric in the United States [22]. All-cause 30-day read-
mission was defined as the proportion of participants admitted 
to a healthcare facility at randomization who had any readmis-
sion within 30 days of discharge. CDI-associated 30-day read-
mission was defined as a 30-day readmission that satisfied ≥1 
of the following criteria: occurrence within 5 days after onset 
of a new episode of CDI, onset of a new CDI episode during 
the readmission, or the discharge diagnosis including terms 
synonymous with CDI, rCDI, or pseudomembranous colitis, as 
recorded on the trial case report form.
For this post hoc analysis, we pooled data from MODIFY 
I and MODIFY II, which were independent trials but nearly 
identical in design [21]. The analysis population was the sub-
set of modified intent-to-treat participants (defined elsewhere 
[21]) who were hospitalized at the time of randomization. 
Subsets of participants at high risk for rCDI were included in 
the subgroup analysis. The proportion of subjects meeting the 
end point definitions was estimated, along with the absolute 
difference in the proportion between the bezlotoxumab and 
placebo groups (with 95% confidence intervals [CIs]) [23]. Risk 
factors included age ≥65 years, severe CDI (severity based on 
Zar score [24]), a history of ≥1 episodes of CDI in the previ-
ous 6 months, infection due to 027 strain, and compromised 
immunity, defined on the basis of medical history or immuno-
suppressive therapy.
RESULTS
Across the 2 MODIFY trials, 781 bezlotoxumab-treated partici-
pants and 773 placebo-treated participants were included in the 
modified intent-to-treat population. Of these, 530 participants 
(67.9%) in the bezlotoxumab group and 520 (67.3%) in the pla-
cebo group were hospitalized at the time of randomization and 
were included in this post hoc analysis. Baseline characteristics, 
including high-risk prognostic factors, were generally similar 
between the bezlotoxumab and placebo groups (Supplementary 
Table S1).
In the 30  days after hospital discharge, participants treated 
with bezlotoxumab had fewer CDI-associated hospital readmis-
sions (absolute difference, −6.1%; 95% CI, −9.5 to −2.8; relative 
difference, −53.4%). Participants treated with bezlotoxumab also 
had fewer all-cause readmissions (absolute difference,  −3.7%; 
95% CI, −9.0 to 1.5; relative difference, −12.1%) than inpatients 
randomized to placebo (Figure 1A), although the difference did 
not reach statistical significance. Bezlotoxumab reduced CDI-
associated hospital readmissions in participants at high risk 
for rCDI (Figure 1B), including those aged ≥65 years or with 
severe CDI. Participants with ≥1 CDI episode in the previous 
6  months, compromised immunity, or infection with the 027 
strain showed fewer rCDIs with bezlotoxumab treatment than 
with placebo treatment; however, the 95% CIs for the difference 
included 0 (Figure 1A).
DISCUSSION
In participants with primary or rCDI treated with antibiotics 
for CDI, bezlotoxumab reduced CDI-associated 30-day hospital 
readmissions compared with placebo. Treatment with bezlotox-
umab was also more effective at reducing CDI-associated hospi-
tal readmissions in participants at high risk for rCDI, including 
those aged ≥65 years and those with severe CDI.
Prevention of rCDI remains a serious unmet medical need, 
especially in patients with high-risk prognostic factors, such as 
the elderly and patients with multiple prior episodes of CDI [25]. 
Several nonantimicrobial experimental approaches are being 
studied to address rCDI [25], such as fecal microbiota trans-
plantation [26] and nontoxigenic C. difficile [27]. Bezlotoxumab 
prevents recurrence by a different mechanism. It binds and neu-
tralizes C. difficile toxin B [21], the primary virulence factor in 
causing CDI symptoms [28]. This novel approach is designed to 
passively provide antibody-mediated immune defense, which 
has been associated with protection against rCDI [29]. Taken 
together, the results of the current analysis, which demonstrate a 
reduction in 30-day CDI-associated hospital readmissions, and 
previously reported findings, demonstrating protective effects 
of bezlotoxumab against rCDI, provide support for using bezlo-
toxumab as a valuable treatment option for patients with CDI.
Lost opportunity costs are unaccounted for in many stud-
ies that focus on the cost of rCDI in acute-care facilities [30]. 
Lessa et al [6] noted that C. difficile was responsible for almost 
half a million infections and was associated with approximately 
29 000 deaths in 2011. Based on economic modeling, high-risk 
susceptible individuals represent 5% of the total hospital pop-
ulation and account for 23% of hospitalized patients with CDI 
[13]. Moreover, the model estimated the economic cost of CDI 
at $5.4 billion in 2014, with most costs due to hospitalization 
[13]. rCDI contributes substantially to the cost and burden of 
CDI, mostly attributable to significantly longer hospital stays 
[16, 19]. Shah et al [31] reported that the cost of rCDI dou-
bled or tripled that of a first episode of CDI. Despite antibiotic 
treatment a quarter of patients experience rCDI, with up to 38% 
experiencing multiple recurrences [3] and with a significantly 
higher likelihood of hospital readmission [20]. 
In the current analysis, however, bezlotoxumab treatment 
was shown to reduce the number of 30-day CDI-associated 
rehospitalizations by approximately 6% overall. Furthermore, 
CDI-associated hospital readmissions were reduced by 8% 
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CDI-related adverse outcomes (participants ≥65 years old and 
those with severe CDI). These results suggest that treatment with 
bezlotoxumab may help reduce some of the costs associated with 
rCDI by reducing CDI-associated hospital readmissions. Of 
note, by preventing 1 recurrence, additional future recurrences 
may also be prevented. It would be of interest to analyze the 
economic impact of bezlotoxumab through further health eco-
nomic evaluations, such as cost-effectiveness analyses.
There were some limitations to these post hoc analyses. 
Although the clinical trial included a broad population with few 
exclusion criteria, a healthier population (compared with real-
world patients with CDI) may have been enrolled, and over-
all readmissions may be underestimated compared with other 
reports in the literature. In addition, the proportion of partici-
pants with a severe baseline CDI episode may have been under-
estimated owing to delay in assessment of CDI severity until the 
antibiotics for CDI had been given for >2 days in the majority of 
participants (>90%). In addition, these post hoc analyses were 
not powered for hypothesis testing. 
In conclusion, the results of the current analysis demon-
strated that treatment with bezlotoxumab, given with C. diffi-
cile active antibacterials was shown to reduce CDI-associated 
rehospitalizations, especially in participants with high-risk 
prognostic factors.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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Figure 1. A, Proportion of inpatients with Clostridium difficile (CDI)–associated and all-cause hospital readmissions within 30 days of discharge. CI, confidence interval. B, 
Summary of CDI-associated readmissions within 30 days of discharge in hospitalized participants with high-risk prognostic factors for recurrent CDI. Participants were defined 
as immunocompromised based on medical history or use of immunosuppressive therapy. Severe CDI was defined as a Zar score ≥2 based on the following scoring system: (1) 
age >60 years (1 point); (2) body temperature >38.3°C (>100°F) (1 point); (3) albumin level <2.5 g/dL (1 point); (4) peripheral white blood cell count >15 000/μL within 48 hours 
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